Search Results - "Spicer, J F"

Epidemiological associations of allergy, IgE and cancer by Josephs, D. H., Spicer, J. F., Corrigan, C. J., Gould, H. J., Karagiannis, S. N.

“…Summary Several epidemiological studies have evaluated potential associations between allergy and risk of malignancy. It remains clear that the relationship…”
Get full text

AllergoOncology – the impact of allergy in oncology: EAACI position paper by Jensen‐Jarolim, E., Bax, H. J., Bianchini, R., Capron, M., Corrigan, C., Castells, M., Dombrowicz, D., Daniels‐Wells, T. R., Fazekas, J., Fiebiger, E., Gatault, S., Gould, H. J., Janda, J., Josephs, D. H., Karagiannis, P., Levi‐Schaffer, F., Meshcheryakova, A., Mechtcheriakova, D., Mekori, Y., Mungenast, F., Nigro, E. A., Penichet, M. L., Redegeld, F., Saul, L., Singer, J., Spicer, J. F., Siccardi, A. G., Spillner, E., Turner, M. C., Untersmayr, E., Vangelista, L., Karagiannis, S. N.

“…Th2 immunity and allergic immune surveillance play critical roles in host responses to pathogens, parasites and allergens. Numerous studies have reported…”
Get full text

Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity by Rudman, S. M., Josephs, D. H., Cambrook, H., Karagiannis, P., Gilbert, A. E., Dodev, T., Hunt, J., Koers, A., Montes, A., Taams, L., Canevari, S., Figini, M., Blower, P. J., Beavil, A. J., Nicodemus, C. F., Corrigan, C., Kaye, S. B., Nestle, F. O., Gould, H. J., Spicer, J. F., Karagiannis, S. N.

“…Summary Background IgE antibodies, sequestered into tissues and retained locally by the high‐affinity IgE receptor, FcɛRI, on powerful effector cells such as…”
Get full text

An immunologically relevant rodent model demonstrates safety of therapy using a tumour‐specific IgE by Josephs, D. H., Nakamura, M., Bax, H. J., Dodev, T. S., Muirhead, G., Saul, L., Karagiannis, P., Ilieva, K. M., Crescioli, S., Gazinska, P., Woodman, N., Lombardelli, C., Kareemaghay, S., Selkirk, C., Lentfer, H., Barton, C., Canevari, S., Figini, M., Downes, N., Dombrowicz, D., Corrigan, C. J., Nestle, F. O., Jones, P. S., Gould, H. J., Blower, P. J., Tsoka, S., Spicer, J. F., Karagiannis, S. N.

“…Background Designing biologically informative models for assessing the safety of novel agents, especially for cancer immunotherapy, carries substantial…”
Get full text

PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours by Dillon, M.T., Boylan, Z., Smith, D., Guevara, J., Mohammed, K., Peckitt, C., Saunders, M., Banerji, U., Clack, G., Smith, S.A., Spicer, J.F., Forster, M.D., Harrington, K.J.

“…•Summary of a protocol for a phase I study combining the ATR inhibitor and palliative radiotherapy.•Study design is discussed.•Study aims and objectives, brief…”
Get full text

Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of Fc epsilon RI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity by Rudman, S M, Josephs, D H, Cambrook, H, Karagiannis, P, Gilbert, A E, Dodev, T, Hunt, J, Koers, A, Montes, A, Taams, L, Canevari, S, Figini, M, Blower, P J, Beavil, A J, Nicodemus, C F, Corrigan, C, Kaye, S B, Nestle, F O, Gould, HJ, Spicer, J F, Karagiannis, S N

“…Background IgE antibodies, sequestered into tissues and retained locally by the high-affinity IgE receptor, Fc epsilon RI, on powerful effector cells such as…”
Get full text

The p53-MDM2 interaction in a cancer-prone family, and the identification of a novel therapeutic target by Picksley, S M, Spicer, J F, Barnes, D M, Lane, D P

“…One approach to developing novel anti-cancer agents is to identify and characterise targets that directly regulate cell growth and are dysfunctional in the…”
Get more information

Does dose affect tumour response in phase I oncology trials of non-cytotoxic agents? by Ghosh, J., Lazaridis, G., Viney, Z., Verma, H., Sheriff, I., Wang, Y., Moller, H., Spicer, J.F., Sarker, D.

Get full text

Necrotic Peyer's patches in association with colonic ischaemia--unhelpful in selecting resection margin by Mathias, M C, Spicer, J F, Guerin, D, McColl, I, Houghton, A D

Get more information

TAX-TORC: An investigator initiated phase I study combining the dual mTORC1/2 inhibitor AZD2014 in combination with weekly paclitaxel in high-grade serous ovarian cancer by Banerji, U., Basu, B., Spicer, J.F., Wilson, R., Hall, E., Sundar, R., Kumar, S., Wu, Y., Coyle, V., Carreira, S., Parmar, M., Dawes, J.C., Banerjee, S., de Bono, J.S.

Get full text

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial by de Bono, Johann S, Concin, Nicole, Hong, David S, Thistlethwaite, Fiona C, Machiels, Jean-Pascal, Arkenau, Hendrik-Tobias, Plummer, Ruth, Jones, Robert Hugh, Nielsen, Dorte, Windfeld, Kristian, Ghatta, Srinivas, Slomovitz, Brian M, Spicer, James F, Yachnin, Jeffrey, Ang, Joo Ern, Mau-Sørensen, Paul Morten, Forster, Martin David, Collins, Dearbhaile, Dean, Emma, Rangwala, Reshma A, Lassen, Ulrik

“…Tisotumab vedotin is a first-in-human antibody–drug conjugate directed against tissue factor, which is expressed across multiple solid tumour types and is…”
Get full text

Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes in Triple-Negative Breast Cancer by Harris, Robert J, Cheung, Anthony, Ng, Joseph C F, Laddach, Roman, Chenoweth, Alicia M, Crescioli, Silvia, Fittall, Matthew, Dominguez-Rodriguez, Diana, Roberts, James, Levi, Dina, Liu, Fangfang, Alberts, Elena, Quist, Jelmar, Santaolalla, Aida, Pinder, Sarah E, Gillett, Cheryl, Hammar, Niklas, Irshad, Sheeba, Van Hemelrijck, Mieke, Dunn-Walters, Deborah K, Fraternali, Franca, Spicer, James F, Lacy, Katie E, Tsoka, Sophia, Grigoriadis, Anita, Tutt, Andrew N J, Karagiannis, Sophia N

“…In breast cancer, humoral immune responses may contribute to clinical outcomes, especially in more immunogenic subtypes. Here, we investigated B lymphocyte…”
Get full text

Absolute bioavailability of PF-01367338 tablets following oral administration in cancer patients by Wang, D. D., Kern, K. A., Carpentieri, M., Zhang, S., Hee, B., Middleton, M. R., Spicer, J. F., Molife, L. R., Plummer, R.

“…Abstract only…”
Get full text

Phase I study of abiraterone acetate (AA) in patients (pts) with estrogen receptor– (ER) or androgen receptor (AR) –positive advanced breast carcinoma resistant to standard endocrine therapies by Basu, B., Ang, J. E., Crawley, D., Folkerd, E., Sarker, D., Blanco-Codesido, M., Moran, K., Wan, S., Dobbs, N., Raynaud, F., Johnston, S. R. D., Dowsett, M., Tutt, A. N. J., Spicer, J. F., Swanton, C., De Bono, J. S.

“…Abstract only…”
Get full text

Phase II, open-label trial to assess the effect of continuous oral afatinib (BIBW 2992) at a daily dose of 50 mg on QTc, pharmacokinetics, and efficacy in relapsed or refractory solid tumors including brain metastases and glioblastoma that is not amenable to other therapy by Kristeleit, H., Puglisi, M., Middleton, G. W., Propper, D., Kelleher, M. T., Trani, L., Denholm, K. A., Wallenstein, G., Stopfer, P., Buschke, S., Uttenreuther-Fischer, M. M., Bent, E., O'Brien, D., Spicer, J. F., Molife, L. R.

“…Abstract only…”
Get full text

A phase II study of sorafenib in malignant mesothelioma with pharmacodynamic imaging using 18 fdg-PET by Irshad, S., Popat, S., Shah, R. N., Burbridge, S., Lal, R., Lang-Lazdunski, L., Viney, Z., Marsden, P., Barrington, S., Spicer, J. F.

“…Abstract only…”
Get full text

A phase II study to assess the efficacy and impact of BIBW 2992 on QTc interval in patients with solid tumors, including brain metastases and recurrent glioblastoma multiforme (GBM) by Trani, L., Alam, S. M., Rudman, S. M., Molife, L. R., Middleton, G. W., Propper, D., Stopfer, P., Uttenreuther-Fischer, M. M., Wallenstein, G., Spicer, J. F.

“…Abstract only…”
Get full text

A phase II, open-label study of ramucirumab (IMC-1121B), an IgG1 fully human monoclonal antibody (MAb) targeting VEGFR-2, in combination with paclitaxel and carboplatin as first-line therapy in patients (pts) with stage IIIb/IV non-small cell lung cancer (NSCLC) by Camidge, D. R., Ballas, M. S., Dubey, S., Haigentz, M., Rosen, P. J., Spicer, J. F., West, H. J., Shah, G. D., Youssoufian, H., Mita, A. C.

“…Abstract only…”
Get full text

A phase I study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma (MM) or renal cell carcinoma (RCC) by Spicer, J. F., Jameson, M. B., Savage, P., Jodrell, D., Rudman, S. M., Erlandsson, F., Acton, G., McKeage, M.

“…Abstract only 3024 Background: AS1409 (huBC1-huIL-12) is a fusion protein combining a humanized antibody specific for the ED-B splice variant of fibronectin…”
Get full text

A phase I study of daily BIBW 2992, an irreversible EGFR/HER-2 dual kinase inhibitor, in combination with weekly paclitaxel by Ang, J., Mikropoulos, C., Stavridi, F., Rudman, S., Uttenreuther-Fisher, M., Shahidi, M., Pemberton, K., Wind, S., de Bono, J., Spicer, J. F.

“…Abstract only e14541 Background: BIBW 2992 is an oral, potent and irreversible inhibitor of both EGFR and HER2 receptor tyrosine kinases. The efficacy of…”
Get full text